
Sign up to save your podcasts
Or
Prof Janet Brown (University of Sheffield, Sheffield, UK) discusses the phase 2/3 STAR trial on treatment cessation versus continuation with tyrosine kinase inhibitors in advanced renal cell carcinoma.
Read the full article:
Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR)
Tell us what you thought about this episode
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
5
11 ratings
Prof Janet Brown (University of Sheffield, Sheffield, UK) discusses the phase 2/3 STAR trial on treatment cessation versus continuation with tyrosine kinase inhibitors in advanced renal cell carcinoma.
Read the full article:
Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR)
Tell us what you thought about this episode
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
756 Listeners
811 Listeners
131 Listeners
325 Listeners
38 Listeners
493 Listeners
58 Listeners
90 Listeners
1,095 Listeners
43 Listeners
318 Listeners
185 Listeners
794 Listeners
23 Listeners
0 Listeners
0 Listeners
2 Listeners
0 Listeners
2 Listeners
1 Listeners
0 Listeners
0 Listeners
1 Listeners
0 Listeners
0 Listeners
1 Listeners
0 Listeners
0 Listeners
0 Listeners
0 Listeners
0 Listeners
169 Listeners
0 Listeners